Vicore announces the Nomination Committee for the 2023 Annual General Meeting

Report this content

Gothenburg, October 20, 2022 – Vicore Pharma Holding AB (publ) (“Vicore”) has appointed the Nomination Committee for the 2023 Annual General Meeting. The three largest shareholders as of August 31, 2022 have been offered to appoint a member to the Nomination Committee each, in accordance with the decision taken at the Annual General Meeting on May 11, 2021.

The Nomination Committee consists of Staffan Lindstrand, appointed by HealthCap VII L.P., Jan Särlvik, appointed by the Fourth Swedish National Pension Fund and Ivo Staijen appointed by HBM Healthcare Investments (Cayman) Ltd. Vicore’s chairman, Jacob Gunterberg, is also a member and acts as the convener of the Nomination Committee.

The task of the Nomination Committee is to prepare and present proposals for the number of board members to be elected by the AGM, the election of a chairman and other members of the board, board fees and, if any, remuneration for committee work, election of a chairman to the Annual General Meeting, election of auditors (if applicable) and auditors’ fees (if applicable) and proposals for rules for the appointment of a nomination committee for the Annual General Meeting 2024.

The Annual General Meeting of Vicore Pharma Holding AB (publ) will take place on May 11, 2023. Shareholders who wish to submit their comments or submit proposals to the Nomination Committee may do so by March 10, 2023, by email to or by letter to Vicore Pharma Holding AB (publ), Kornhamnstorg 53, 111 27 Stockholm. The Nomination Committee's proposal will be presented in the notice convening the AGM and on the company's website.

For further information, please contact:

Jacob Gunterberg, Chairman of the Board, tel: +46 70 975 10 15

This information was submitted for publication on October 20, 2022 at 09:00 CET.

About Vicore Pharma Holding AB (publ)

Vicore is an innovative Swedish clinical-stage pharmaceutical company dedicated to creating life-changing treatments in diseases where the Angiotensin II type 2 receptor (AT2R) has a central protective role. The company currently has four development programs, VP01, VP02, VP03 and VP04. VP01 aims to develop the substance C21 for the treatment of idiopathic pulmonary fibrosis (IPF) and pulmonary artery hypertension (PAH). VP02 is a new formulation and delivery route of thalidomide and focuses on the underlying disease and the severe cough associated with IPF. In the VP03 program new AT2 receptor agonists are developed. VP04 is a clinically validated digital therapeutic in development for IPF patients.

The company’s shares (VICO) are listed on Nasdaq Stockholm’s main market. For more information, see